The Alzheimer’s disease (AD) diagnosis and therapy market is expanding with increasing number of cases worldwide. The current scenario shows bright outlook for diagnosis market. As early diagnosis of AD is not possible, there is a strong need of an early detection technique. United States, Europe and Japan are the three major markets for the treatment of AD. In China, the diagnosis and drug treatment of Alzheimer’s disease is extremely low, which represents a potential opportunity for market players.
The worldwide Alzheimer disease market is led by sales of Eisai/Pfizer and Aricept. Eisai/Pfizer’s Aricept (donepezil) and Forest pharmaceutical’s Namenda (memantine) are the market leaders in the United States. After cardiovascular diseases and cancer, AD is the third largest market in the world in terms of cost of treatment of the disease.
Aging population is a major cause of increasing number of Alzheimer patients and driving AD diagnosis and treatment market. Urbanization also contributes to the growing AD market. The unmet clinical needs are driving competitors to focus on R&D which ultimately leads to new product introduction and helps in market growth.
The present report analyzes Alzheimer’s disease treatment and diagnosis market and discusses major drugs being used for the treatment of AD in United States, Japan and China. It analyses major growth drivers and opportunities present in the market. The report also discusses competition prevailing in the industry and an overview of the leading companies and their business strategies. The section on market forecast helps market players to develop business strategies accordingly.